Publications in collaboration with researchers from Mayo Clinic (47)

2024

  1. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  2. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

    Haematologica, Vol. 108, Núm. 8, pp. 2192-2204

  2. Global disparities in patients with multiple myeloma: a rapid evidence assessment

    Blood Cancer Journal, Vol. 13, Núm. 1

  3. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311

2022

  1. Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

    Current Medical Research and Opinion, Vol. 38, Núm. 10, pp. 1759-1767

  2. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384

  3. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice

    The Lancet Haematology, Vol. 9, Núm. 2, pp. e162-e165

  4. Smoldering multiple myeloma current treatment algorithms

    Blood cancer journal, Vol. 12, Núm. 9, pp. 129

  5. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Blood, Vol. 139, Núm. 4, pp. 492-501

  6. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)

    Annals of Hematology

  2. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507

  3. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  4. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  5. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

  6. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

    Annals of Hematology, Vol. 99, Núm. 8, pp. 1793-1804

  2. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

  3. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3019-3027